The Bloom #184 Free Edition being the White Rabbit

Normally, I would email you once every two weeks.

But it's been nearly six weeks since the last Bloom.

I'm fully caught up with the latest research (also see the recap for August), but because of family circumstances, the next edition might come in a bit later too.

See some of the most interesting studies below, and the full updates on our papers page and link overview (for paid subscribers only).

Floris - Founder of Blossom

ps there are some great psychedelic conferences happening this fall, here is a quick overview

• ​Borealis (Stockholm, Sweden), Sep 26-27 (research)
• ​Psykedeelit (Turku, Finland), Oct 2-4 (research)
• ​Awakening (Los Angeles), Oct 2-4 (general audience)
• ​Inawe (Madrid, Spain), Oct 2-4 (research)
• ​ALPS (Geneva, Switzerland), Oct 24-25 (research)
• ​Fuertedélica (Fuerteventura, Spain), Nov 7-8 (research)
• ​Psychedelic Lived Experiences Summit (online), Nov 21-23 (patient voices)
• ​PhilaDelic Forum (Philadelphia/online), Nov 22nd (research & real-world implementation)
• ​PSYCH Symposium (London), Dec 4th (industry & research)

pps for Delphi I spoke about psychedelics and reimbursement in Europe, replay the recording (30min) and find all slides and an edited transcript there too

Latest Psychedelic Research

1 Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder​

This Phase IIb randomised, double-blind, placebo-controlled trial (n=198) found that single doses of 100 µg and 200 µg of MM120 (lysergide D-tartrate) significantly reduced anxiety symptoms at 4 weeks in adults with moderate to severe generalised anxiety disorder (GAD), with dose-dependent effects and adverse events including visual perceptual changes, nausea, and headache.

2 Ayahuasca-assisted meaning reconstruction therapy as an early resource for bereavement​

This three-arm open-label study (n=84) found that ayahuasca-assisted meaning reconstruction therapy (A-MR) produced significantly greater reductions in severe grief compared to meaning reconstruction therapy alone (d=0.86) or no treatment (d=1.07), with the A-MR group showing the largest effect size (d=2.44) and additional improvements in prolonged grief symptoms, post-traumatic growth, and quality of life.

3 Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder​

This Phase II, nonrandomized open-label trial (n=22) tested a single 25 mg dose of psilocybin with psychological support in adults with PTSD. It found the treatment to be safe and well-tolerated, with common side effects such as headache, nausea, crying, and fatigue resolving quickly. Clinically meaningful reductions in PTSD symptoms were observed at weeks 4 and 12, alongside improvements in functioning and quality of life.

4 Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis​

This cost-effectiveness analysis found that psilocybin-assisted therapy (PAT) for treatment-resistant depression (TRD) may offer economic value at $5,000 or less per treatment course, yielding an incremental cost-effectiveness ratio of $117,517 per QALY gained over 12 months, with cost-effectiveness highly sensitive to treatment price (95% probability at $3,000 vs 1% at $10,000).

5 The Potential Economic and Public Health Impact of MDMA‐Assisted Group Therapy for PTSD in Ukraine​

This decision analysis model study (n=1000 simulated PTSD patients) evaluates the cost-effectiveness of group MDMA-assisted therapy with supplemental individual therapy for PTSD in Ukraine. It finds treatment costs $1.1M, averts 19.2 deaths, and gains 717 QALYs over 3 years, with an incremental cost-effectiveness ratio of $1537 per QALY. From a societal perspective, the intervention generates $2.6M in net savings, and scaling to 50% of eligible patients over 10 years could save 48,000 lives and gain 1.5M QALYs.

6 Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness​

This double-blind placebo-controlled trial (n=35) found that psilocybin-assisted psychotherapy (25mg) significantly reduced depression and anxiety symptoms in adults with life-threatening illnesses compared to an active placebo (100mg niacin), with benefits sustained at 26 weeks and improvements in spiritual well-being, quality of life, demoralisation, and death anxiety.

More Research

• ​N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences​
• ​A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers​
• ​Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice​
• ​Resilience and Brain Changes in Long-Term Ayahuasca Users: Insights From Psychometric and fMRI Pattern Recognition​
• ​Ayahuasca-inspired DMT/harmine formulation alters creative thinking dynamics during artistic creation​
• ​DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers​
• ​Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat​
• ​The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation​

New on Blossom

1 Psychedelic Research Recap August​

August highlighted both the clinical potential and the societal relevance of psychedelic therapies. Psilocybin remained at the forefront, with trials showing safety and tolerability in PTSD patients, significant antidepressant and anxiolytic effects in those with life-threatening illness, and robust symptom improvements among veterans with traumatic brain injuries following retreat-based use. Economic evaluations underscored the feasibility of implementation, with psilocybin for treatment-resistant depression modelled as cost-effective at lower price points, and MDMA group therapy for PTSD in Ukraine projected to deliver major public health gains and cost savings.

Beyond psilocybin and MDMA, the field expanded in scope. Preclinical work demonstrated that chronic low-dose LSD may not carry the same cardiovascular risks as fenfluramine or serotonin, while the psychoplastogen tabernanthalog (TBG) induced neuroplasticity and sustained antidepressant-like effects without immediate early gene activation. Research on ayahuasca and related formulations revealed altered brain-emotion patterns in long-term users, alongside disruptions in creative cognition during artistic tasks.

2 Psychedelic Research Links 2025​

A comprehensive overview of all psychedelic research that has come out this year. We cover the research per month and provide a one-sentence summary for each new publication. After the full summary is added, a link to Blossom's review is added to the papers included in our database.
​

Spotlight

No spotlight this time.

Molenvaart 76, Anna Paulowna, NH 1761AL
​Unsubscribe · Preferences​